I-Mab
NASDAQ:IMAB
I-Mab
NASDAQ:IMAB
Price:
3.98
USD
0.51%
Market Closed
Market Cap:
$325m
I-Mab
Research & Development
Last
Value
3 Years
3Y
CAGR
5 Years
5Y
CAGR
10 Years
10Y
CAGR
|
See Also
I-Mab
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
I-Mab
NASDAQ:IMAB
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Research & Development
-¥13.6B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Research & Development
-¥2.1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
RemeGen Co Ltd
SSE:688331
|
Research & Development
-¥1.4B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Research & Development
-¥1.2B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
Research & Development
-¥1.2B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
No Stocks Found
I-Mab
Glance View
I-Mab operates as a clinical stage biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-01-17.
IMAB
Intrinsic Value
Not Available
